References:

1. Food and Drug Administration. Center for Biologics Evaluation and Research (CBER). CBER clinical review of studies submitted in support of
   licensure of ProQuad. https:// www.fda.gov/media/165978/download. Accessed July 2026.
2. ProQuad Summary of Product Characteristics.
3. Rüger G, Gabutti G, Rümke H, et al. Safety of a 2-dose regimen of a combined measles, mumps, rubella and varicella live vaccine manufactured
   with recombinant human albumin. Pediatr Infect Dis J. 2012;31(11):1166-1172.

AE-QDX-00012 | Exp: 25 July 2028